• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

同期放化疗治疗局部晚期宫颈癌患者盆腔淋巴结状态的临床影响。

Clinical Impact of Pelvic Lymph Node Status in Locally Advanced Cervical Cancer Patients Treated by Concurrent Chemoradiation Therapy.

机构信息

Radiation Oncology Unit, Department of Radiology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Thailand.

Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Thailand.

出版信息

Asian Pac J Cancer Prev. 2021 Feb 1;22(2):491-497. doi: 10.31557/APJCP.2021.22.2.491.

DOI:10.31557/APJCP.2021.22.2.491
PMID:33639665
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8190339/
Abstract

OBJECTIVE

To explore the treatment outcomes of locally advanced cervical cancer (LACC) patients with pelvic lymph node enlargement (PLNE) or stage IIIC1 when compared with no PLNE and unknown PLN status (UNK).

MATERIALS AND METHODS

Retrospective cohort study was designed by matching with the ratio of 1:4:4 for patients with PLNE, no PLNE and UNK between 2003 and 2017. The main factor which was used to match was clinical staging.

RESULTS

All 360 LACC patients who treated as concurrent chemoradiation therapy (CCRT) were composed of 40 with PLNE, 160 with no PLNE and 160 with UNK. The majority of tumor histology (78.9%) was squamous cell carcinoma and 51.1% were diagnosed in stage IIB. Five-year progression free survival rates of patients with PLNE, no PLNE and UNK were 42.7%, 64.5% and 59.0%, respectively (P = 0.191), and corresponding with 5-year overall survival rates of 57.0%, 66.0% and 61.9% (P = 0.608). Patients with PLNE had local recurrence (LR) at 22.5%, compared with no PLNE at 11.3% and UNK at 11.9%. The most common site of LR for patients with PLNE was PLN with odds ratio of 19.7 when using no PLNE as reference (P < 0.001). There was no statistically significant difference between distant metastasis rates in PLN statuses of patients with PLNE, no PLNE and UNK at 20.6%, 30.0% and 26.3%, respectively.  Conclusions: LACC patients with PLNE had a trend of poorer survival rates than patients with no PLNE, while treatment outcomes of patients with UNK were not inferior to no PLNE.
.

摘要

目的

探讨局部晚期宫颈癌(LACC)患者盆腔淋巴结肿大(PLNE)或 IIIC1 期与无 PLNE 和未知 PLN 状态(UNK)患者的治疗结果。

材料与方法

采用 1:4:4 比例的病例对照研究,对 2003 年至 2017 年间 PLNE、无 PLNE 和 UNK 的患者进行匹配。主要匹配因素为临床分期。

结果

360 例接受同期放化疗(CCRT)的 LACC 患者中,PLNE 组 40 例,无 PLNE 组 160 例,UNK 组 160 例。肿瘤组织学类型以鳞癌为主(78.9%),ⅡB 期占 51.1%。PLNE、无 PLNE 和 UNK 患者的 5 年无进展生存率分别为 42.7%、64.5%和 59.0%(P = 0.191),相应的 5 年总生存率分别为 57.0%、66.0%和 61.9%(P = 0.608)。PLNE 组局部复发率(LR)为 22.5%,无 PLNE 组为 11.3%,UNK 组为 11.9%。PLNE 患者 LR 最常见的部位是 PLN,与无 PLNE 相比,比值比为 19.7(P < 0.001)。PLNE、无 PLNE 和 UNK 患者的远处转移率分别为 20.6%、30.0%和 26.3%,差异无统计学意义。

结论

与无 PLNE 患者相比,PLNE 的 LACC 患者生存率呈下降趋势,而 UNK 患者的治疗结果并不逊于无 PLNE。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9427/8190339/6011e80ea7d8/APJCP-22-491-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9427/8190339/fd9631eed259/APJCP-22-491-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9427/8190339/9d9e3e214970/APJCP-22-491-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9427/8190339/31d990744612/APJCP-22-491-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9427/8190339/6011e80ea7d8/APJCP-22-491-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9427/8190339/fd9631eed259/APJCP-22-491-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9427/8190339/9d9e3e214970/APJCP-22-491-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9427/8190339/31d990744612/APJCP-22-491-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9427/8190339/6011e80ea7d8/APJCP-22-491-g004.jpg

相似文献

1
Clinical Impact of Pelvic Lymph Node Status in Locally Advanced Cervical Cancer Patients Treated by Concurrent Chemoradiation Therapy.同期放化疗治疗局部晚期宫颈癌患者盆腔淋巴结状态的临床影响。
Asian Pac J Cancer Prev. 2021 Feb 1;22(2):491-497. doi: 10.31557/APJCP.2021.22.2.491.
2
Para-aortic and pelvic lymphadenectomy in locally advanced cervical cancer with pelvic lymph node metastasis.局部晚期宫颈癌伴盆腔淋巴结转移的腹主动脉旁和盆腔淋巴结切除术。
World J Surg Oncol. 2024 Sep 30;22(1):262. doi: 10.1186/s12957-024-03540-0.
3
The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy.基于盆腔淋巴结特征对接受同步放化疗的局部晚期宫颈鳞状细胞癌患者的预后及风险分层
Int J Gynecol Cancer. 2016 Oct;26(8):1472-9. doi: 10.1097/IGC.0000000000000778.
4
[Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].[同步放化疗治疗晚期宫颈鳞状细胞癌患者远处转移的结局及预后因素]
Zhonghua Fu Chan Ke Za Zhi. 2015 Feb;50(2):125-30.
5
Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment.根治性治疗后宫颈癌孤立性腹主动脉旁淋巴结复发患者的挽救性治疗比较。
Radiat Oncol. 2019 Dec 26;14(1):236. doi: 10.1186/s13014-019-1442-6.
6
Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.局部晚期宫颈癌患者同步放化疗的疗效和预后因素。
Radiat Oncol. 2022 Aug 17;17(1):142. doi: 10.1186/s13014-022-02115-1.
7
Outcome of international Federation of gynecology and obstetrics stage IIb cervical cancer from 2003 to 2012: an evaluation of treatments and prognosis: a retrospective study.2003年至2012年国际妇产科联盟IIb期宫颈癌的治疗结果:治疗与预后评估:一项回顾性研究
Int J Gynecol Cancer. 2015 Jun;25(5):910-8. doi: 10.1097/IGC.0000000000000430.
8
[Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].[术后同步放化疗对具有中危因素的早期宫颈癌患者的疗效分析]
Zhonghua Zhong Liu Za Zhi. 2018 Jun 23;40(6):462-466. doi: 10.3760/cma.j.issn.0253-3766.2018.06.012.
9
Patterns of spread in node-positive cervical cancer: the relationship between local control and distant metastases.淋巴结阳性宫颈癌的扩散模式:局部控制与远处转移之间的关系。
Cancer J Sci Am. 1996 Sep-Oct;2(5):256-62.
10
Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.根治性子宫切除术及辅助放疗或放化疗治疗宫颈腺癌或腺鳞癌的临床行为和结局。
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):420-7. doi: 10.1016/j.ijrobp.2011.12.013. Epub 2012 Feb 24.

引用本文的文献

1
Prediction of Recurrent Cervical Cancer in 2-Year Follow-Up After Treatment Based on Quantitative and Qualitative Magnetic Resonance Imaging Parameters: A Preliminary Study.基于定量和定性磁共振成像参数对治疗后 2 年随访中复发性宫颈癌的预测:一项初步研究。
Ann Surg Oncol. 2023 Sep;30(9):5577-5585. doi: 10.1245/s10434-023-13756-1. Epub 2023 Jun 25.
2
Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer.FIGO 分期 IIIC1 期宫颈癌患者的宫旁侵犯与生存降低。
J Gynecol Oncol. 2023 Jul;34(4):e46. doi: 10.3802/jgo.2023.34.e46. Epub 2023 Mar 13.
3
Whether individualized dose escalation should be recommended for lymph nodes with different sizes in the definitive radiotherapy of cervical cancer?

本文引用的文献

1
A Risk Stratification for Patients with Cervical Cancer in Stage IIIC1 of the 2018 FIGO Staging System.2018FIGO 分期系统中 IIIC1 期宫颈癌患者的风险分层。
Sci Rep. 2020 Jan 15;10(1):362. doi: 10.1038/s41598-019-57202-3.
2
Comparing survival outcomes between surgical and radiographic lymph node assessment in locally advanced cervical cancer: A propensity score-matched analysis.比较局部晚期宫颈癌手术与影像学淋巴结评估的生存结局:倾向评分匹配分析。
Gynecol Oncol. 2020 Feb;156(2):320-327. doi: 10.1016/j.ygyno.2019.12.009. Epub 2019 Dec 14.
3
The variable impact of positive lymph nodes in cervical cancer: Implications of the new FIGO staging system.
宫颈癌根治性放疗中,对于不同大小的淋巴结是否应推荐个体化剂量递增?
Radiat Oncol. 2022 Oct 20;17(1):167. doi: 10.1186/s13014-022-02132-0.
宫颈癌阳性淋巴结的可变影响:新 FIGO 分期系统的意义。
Gynecol Oncol. 2020 Jan;156(1):85-92. doi: 10.1016/j.ygyno.2019.10.025. Epub 2019 Nov 16.
4
Clinical significance of lymph node size in locally advanced cervical cancer treated with concurrent chemoradiotherapy.同步放化疗治疗局部晚期宫颈癌时淋巴结大小的临床意义
Yeungnam Univ J Med. 2019 May;36(2):115-123. doi: 10.12701/yujm.2019.00143. Epub 2019 Feb 21.
5
Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines.2018 年国际妇产科联合会宫颈癌分期指南的预后性能。
Obstet Gynecol. 2019 Jul;134(1):49-57. doi: 10.1097/AOG.0000000000003311.
6
Revised FIGO staging for carcinoma of the cervix uteri.FIGO 修订版子宫颈癌分期。
Int J Gynaecol Obstet. 2019 Apr;145(1):129-135. doi: 10.1002/ijgo.12749. Epub 2019 Jan 17.
7
Validation of the 2018 FIGO cervical cancer staging system.FIGO 2018 宫颈癌分期系统的验证。
Gynecol Oncol. 2019 Jan;152(1):87-93. doi: 10.1016/j.ygyno.2018.10.026. Epub 2018 Oct 30.
8
Cancer of the cervix uteri.子宫颈癌。
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:22-36. doi: 10.1002/ijgo.12611.
9
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
10
Prognostic significance of lymph node ratio in node-positive cervical cancer patients.淋巴结比率在淋巴结阳性宫颈癌患者中的预后意义。
Medicine (Baltimore). 2018 Jul;97(30):e11711. doi: 10.1097/MD.0000000000011711.